NCT01959503已完成不适用
A Prospective, Randomized Study to Compare Progel Vascular Sealant to Gelfoam Plus as an Adjunct for the Control of Bleeding in Subjects Undergoing Thoracic Aortic Surgery
C. R. Bard37 个研究点 分布在 1 个国家目标入组 158 人开始时间: 2013年11月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 158
- 试验地点
- 37
- 主要终点
- Time to Achieve Hemostasis at the Aortic Anastomotic Suture Line From the Time Surgical Clamps Are Released to Cessation of Leakage at the Treated Anastomotic Site With Either Progel or Gelfoam.
研究概览
简要总结
This study is being conducted to evaluate the safety and effectiveness of the Progel Vascular Sealant for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage.
详细描述
The primary objective of this clinical study is to compare the time to hemostasis at the aortic anastomotic suture line in subjects receiving Progel (Test group) to that in subjects receiving Gelfoam Plus (Control group) on anastomotic suture lines involving the aortic valve, ascending aorta, or aortic arch while on cardiopulmonary bypass.
The primary endpoint of this study is the time to achieve hemostasis at the aortic anastomotic suture line from the time surgical clamps are released to cessation of leakage at the treated anastomotic site with either Progel (Test) or Gelfoam Plus (Control).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be ≥ 18 years of age.
- •Subject is scheduled for elective, primary thoracic surgery involving the aortic valve, ascending aorta, or aortic arch on cardiopulmonary bypass.
- •Subject has an expected life expectancy> 6 months.
- •Subject is willing and able to comply with all aspects of the study including follow-up schedule.
- •Subject or authorized representative, has the ability to provide voluntary written informed consent.
- •Intra-operative Inclusion Criteria:
- •Subject is able to undergo an antegrade cardioplegia injection for evaluation of a leak at the aortic anastomotic site(s) during the procedure.
- •Following this injection, subject has a leaking site where a topical sealant/hemostatic agent may be used to control bleeding.
排除标准
- •Subject has Type A or other acute thoracic aortic dissection.
- •Subject has undergone prior thoracic surgery (open thoracotomy not including interventional cardiology procedures).
- •Subject is undergoing a planned concomitant procedure other than coronary artery bypass graft (CABG).
- •Subject has a previous organ transplant.
- •Subject has known or suspected preoperative coagulation disorder.
- •Subject is allergic to human thrombin or has a history of allergic reactions after application of human thrombin.
- •Subject is allergic to protamine.
- •Subject has a Left Ventricular Assist Device (LVAD) or planned to receive an LVAD.
- •Subject is undergoing emergency surgery.
- •Subject is in chronic renal failure.
- •Subject has a hematocrit < 21% pre-operatively.
- •Subject has a serum creatinine ≥2.5 mg/dl at baseline or is currently on dialysis.
- •Subject has a cardiac ejection fraction <25%.
- •Subject is scheduled for another cardiac surgery within 30 days of enrollment.
- •Subject has an active or latent infection which is systemic or at the intended surgery site.
- •Subject is immuno-compromised such as that resulting from chronic oral steroid use, chemotherapeutic agents, or immune deficiency disorders.
- •Subject is pregnant by a positive pregnancy test or has plans to become pregnant during the study period or is currently breast-feeding.
- •Subject is unwilling to receive blood products.
- •Subject has participated in another investigational research study within 30 days of enrollment.
- •In the opinion of the investigator, the subject has a clinical condition that would preclude the use of the study device, preclude the subject from completing the follow-up requirements, or would complicate the evaluation of this study.
结局指标
主要结局
Time to Achieve Hemostasis at the Aortic Anastomotic Suture Line From the Time Surgical Clamps Are Released to Cessation of Leakage at the Treated Anastomotic Site With Either Progel or Gelfoam.
时间窗: 0 seconds to 600 seconds
次要结局
- Proportion of Subjects Who Achieve Immediate Hemostasis, Defined as 0 Seconds, at All Treated Aortic Anastomotic Suture Lines Following Assigned Treatment.(0 seconds to 10 minutes)
- Chest Tube Drainage Volume Following Surgery.(24 hours post procedure)
- Proportion of Subjects Who Received Transfusion Within 24 Hours Following Surgery(24 hours post procedure)
- Time Between Cross Clamp Removal and Request of Surgical Wires for Sternal Closure.(Intra-procedurally)
- Incidence of Reoperations for Aortic Bleeding Complications Following Treatment.(30 days post procedure)
- Proportion of Subjects With Device-Related Serious Adverse Events Following Assigned Treatment Through 30 Days(30 days post procedure)
- Proportion of Subjects Who Achieve Successful Hemostasis at All Treated Aortic Anastomotic Suture Lines Following Assigned Treatment.(5 minutes after application)
研究者
研究点 (37)
Loading locations...
相似试验
撤回
3 期
Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing DecorticationLung DiseasesMesotheliomaNCT02511600M.D. Anderson Cancer Center
已完成
不适用
Progel® Pleural Air Leak Sealant (PALS) in Video and Robotic Assisted Thoracoscopic SurgeryPulmonary DiseaseNCT01867658C. R. Bard207
已完成
2 期
A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart FailureHeart FailureDilated CardiomyopathyNCT01311791LoneStar Heart, Inc.78
尚未招募
2 期
Effect of Pregabalin Gel in Controlling Cervical Dentin HypersensitivityDentin SensitivityNCT06417580Jesuína Lamartine Nogueira Araújo18
尚未招募
不适用
Evaluation of the EF192B Protection Versus No TreatmentSkin LesionsSkin CareNCT06752460Eurofarma Laboratorios S.A.72